SELECT trial: Semaglutide reduces the risk of MACE by 20% in adults with overweight or obesity
Results from the SELECT cardiovascular outcomes trial has revealed that semaglutide 2.4mg demonstrated a statistically significant and...
top of page
Browse by category
Search
Browse by tag
bottom of page